Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction

Critical Care Clinics

Volumn 23, Issue 4, 2007, Pages 709-735

  Bhatheja, Rohit ^a,b   Mukherjee, Debabrata ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; DISEASE MARKER; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; KINESIOTHERAPY; LONG TERM CARE; LOW FAT DIET; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; ST SEGMENT ELEVATION; TREADMILL EXERCISE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; CARDIOVASCULAR AGENTS; CLINICAL PROTOCOLS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RISK ASSESSMENT;

EID: 35448990170     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2007.07.003     Document Type: Review

References (77)

1. American Heart Association/American Stroke Association-Heart Disease and Stroke Statistics. 2006.
2. Fernandez-Ortiz A., Badimon J.J., Falk E., et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23 (1994) 1562-1569
3. van der Wal A.C., Becker A.E., van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
4. Fitzgerald D.J., Roy L., Catella F., et al. Platelet activation in unstable coronary disease. N Engl J Med 315 (1986) 983-989
5. Holt J.C., Harris M.E., Holt A.M., et al. Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and beta-thromboglobulin. Biochemistry 25 (1986) 1988-1996
6. Baumgartner H.R., and Born G.V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature 218 (1968) 137-141
7. Coller B.S. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 16 Suppl L (1995) 11-15
8. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
9. Braunwald E. Unstable angina. A classification. Circulation 80 (1989) 410-414
10. Holmes Jr. D.R., Berger P.B., Hochman J.S., et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 100 (1999) 2067-2073
11. Cannon C.P., McCabe C.H., Stone P.H., et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol 30 (1997) 133-140
12. Eisenberg P.R., Kenzora J.L., Sobel B.E., et al. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. J Am Coll Cardiol 18 (1991) 898-903
13. Slater D.K., Hlatky M.A., Mark D.B., et al. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. Am J Cardiol 60 (1987) 766-770
14. Savonitto S., Ardissino D., Granger C.B., et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 281 (1999) 707-713
15. Savonitto S., Cohen M.G., Politi A., et al. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. Eur Heart J 26 (2005) 2106-2113
16. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
17. Lindahl B., Venge P., and Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 93 (1996) 1651-1657
18. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 335 (1996) 1342-1349
19. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 (2000) 835-842
20. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (2004) 2727-2733
21. Bhatt D.L., Roe M.T., Peterson E.D., et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 292 (2004) 2096-2104
22. Kerensky R.A., Wade M., Deedwania P., et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 39 (2002) 1456-1463
23. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
24. Cheitlin M.D., Hutter Jr. A.M., Brindis R.G., et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 33 (1999) 273-282
25. Yusuf S., Wittes J., and Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 260 (1988) 2259-2263
26. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
27. Gibson R.S., Hansen J.F., Miserly F., et al. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies. Am J Cardiol 86 (2000) 275-279
28. Pepine C.J., Faich G., and Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 21 (1998) 633-641
29. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
30. Theroux P., Ouimet H., McCans J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319 (1988) 1105-1111
31. Lewis Jr. H.D., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309 (1983) 396-403
32. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990) 827-830
33. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2 (1988) 349-360
34. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
35. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
36. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
37. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
38. Balsano F., Rizzon P., Violi F., et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 82 (1990) 17-26
39. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
40. Kleiman N.S. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 138 (1999) 263-275
41. Heidenreich P.A., Alloggiamento T., Melsop K., et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 38 (2001) 478-485
42. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
43. Bolognese L., Falsini G., Liistro F., et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 47 (2006) 522-528
44. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
45. Peterson E.D., Pollack Jr. C.V., Roe M.T., et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 42 (2003) 45-53
46. Becker R.C., Ball S.P., Eisenberg P., et al. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 137 (1999) 59-71
47. Oler A., Whooley M.A., Oler J., et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276 (1996) 811-815
48. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 337 (1997) 688-698
49. Prager N.A., Abendschein D.R., McKenzie C.R., et al. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92 (1995) 962-967
50. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337 (1997) 447-452
51. Goodman S.G., Cohen M., Bigonzi F., et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 36 (2000) 693-698
52. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100 (1999) 1593-1601
53. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
54. Swahn E., and Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group. Am J Cardiol 80 (1997) 25E-29E
55. Mukherjee D., and Topol E.J. The role of low-molecular-weight heparin in cardiovascular diseases. Prog Cardiovasc Dis 45 (2002) 139-156
56. Bates E.R. Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep 3 (2001) 348-354
57. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 353 (1999) 429-438
58. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
59. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
60. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
61. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715
62. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 360 (2002) 743-751
63. Mahoney E.M., Jurkovitz C.T., Chu H., et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288 (2002) 1851-1858
64. Anderson H.V., Cannon C.P., Stone P.H., et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 26 (1995) 1643-1650
65. Boden W.E., O'Rourke R.A., Crawford M.H., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 338 (1998) 1785-1792
66. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 (2005) 1095-1104
67. Lagerqvist B., Husted S., Kontny F., et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 40 (2002) 1902-1914
68. Spacek R., Widimsky P., Straka Z., et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 23 (2002) 230-238
69. Hoenig M., Doust J., Aroney C., et al. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 3 (2006) CD004815
70. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
71. Dupuis J., Tardif J.C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
72. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
73. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
74. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
75. Wiviott S.D., Cannon C.P., Morrow D.A., et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46 (2005) 1411-1416
76. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
77. Mukherjee D., Fang J., Chetcuti S., et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004) 745-749